RT Journal Article
SR Electronic
T1 Suppression of COVID-19 outbreak in the municipality of Vo’, Italy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20053157
DO 10.1101/2020.04.17.20053157
A1 Lavezzo, Enrico
A1 Franchin, Elisa
A1 Ciavarella, Constanze
A1 Cuomo-Dannenburg, Gina
A1 Barzon, Luisa
A1 Vecchio, Claudia Del
A1 Rossi, Lucia
A1 Manganelli, Riccardo
A1 Loregian, Arianna
A1 Navarin, Nicolò
A1 Abate, Davide
A1 Sciro, Manuela
A1 Merigliano, Stefano
A1 Decanale, Ettore
A1 Vanuzzo, Maria Cristina
A1 Saluzzo, Francesca
A1 Onelia, Francesco
A1 Pacenti, Monia
A1 Parisi, Saverio
A1 Carretta, Giovanni
A1 Donato, Daniele
A1 Flor, Luciano
A1 Cocchio, Silvia
A1 Masi, Giulia
A1 Sperduti, Alessandro
A1 Cattarino, Lorenzo
A1 Salvador, Renato
A1 Gaythorpe, Katy A. M.
A1 ,
A1 Brazzale, Alessandra R.
A1 Toppo, Stefano
A1 Trevisan, Marta
A1 Baldo, Vincenzo
A1 Donnelly, Christl A.
A1 Ferguson, Neil M.
A1 Dorigatti, Ilaria
A1 Crisanti, Andrea
YR 2020
UL http://medrxiv.org/content/early/2020/04/18/2020.04.17.20053157.abstract
AB On the 21st of February 2020 a resident of the municipality of Vo’, a small town near Padua, died of pneumonia due to SARS-CoV-2 infection1. This was the first COVID-19 death detected in Italy since the emergence of SARS-CoV-2 in the Chinese city of Wuhan, Hubei province2. In response, the regional authorities imposed the lockdown of the whole municipality for 14 days3. We collected information on the demography, clinical presentation, hospitalization, contact network and presence of SARS-CoV-2 infection in nasopharyngeal swabs for 85.9% and 71.5% of the population of Vo’ at two consecutive time points. On the first survey, which was conducted around the time the town lockdown started, we found a prevalence of infection of 2.6% (95% confidence interval (CI) 2.1-3.3%). On the second survey, which was conducted at the end of the lockdown, we found a prevalence of 1.2% (95% CI 0.8-1.8%). Notably, 43.2% (95% CI 32.2-54.7%) of the confirmed SARS-CoV-2 infections detected across the two surveys were asymptomatic. The mean serial interval was 6.9 days (95% CI 2.6-13.4). We found no statistically significant difference in the viral load (as measured by genome equivalents inferred from cycle threshold data) of symptomatic versus asymptomatic infections (p-values 0.6 and 0.2 for E and RdRp genes, respectively, Exact Wilcoxon-Mann-Whitney test). Contact tracing of the newly infected cases and transmission chain reconstruction revealed that most new infections in the second survey were infected in the community before the lockdown or from asymptomatic infections living in the same household. This study sheds new light on the frequency of asymptomatic SARS-CoV-2 infection and their infectivity (as measured by the viral load) and provides new insights into its transmission dynamics, the duration of viral load detectability and the efficacy of the implemented control measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Veneto Region and was jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. I.D. acknowledges research funding from a Sir Henry Dale Fellowship funded by the Royal Society and Wellcome Trust [grant 213494/Z/18/Z]. L.O. and G.C.D. acknowledge research funding from The Royal Society. We thank F. Caldart, M.D., G. Castelli, M.D., M. Drigo, M.D., L. Fava, M.D., B. Labella, M.D., M. Nicoletti, M.D., E. Nieddu, M.D. for assistance in data collection and consistency check, F. Bosa and G. Rupolo from the Italian Red Cross for the support in patient samplings.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset is available as a supplementary file.